ACE-031
Also known as: ACVR2B-Fc
ACE-031 (ramatercept) is a soluble fusion protein of the activin receptor IIB (ActRIIB) extracellular domain and human IgG1 Fc, developed by Acceleron Pharma as a myostatin/activin ligand trap for muscle-wasting disorders. Clinical development was HALTED in 2011 after unexpected vascular adverse events (epistaxis, telangiectasia) attributed to off-target BMP-9/10 inhibition. NOT FDA-approved; all further development was terminated. Now sold only as a grey-market research chemical. WADA-prohibited (myostatin inhibitor).
Pricing for ACE-031
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
No COAs on file for ACE-031
No third-party tests indexed yet. Phase 2 will surface more vendor evidence as the dataset grows.
18 citations indexed for ACE-031
Study · 2026
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus)
Pharmacological blockade of ligands for the activin receptor type IIB (ActRIIB) e.g., myostatin and activin A is associated with improvements in murine skeletal muscle mass and function.
animal · 2026
Fibro-Adipogenic Progenitors Regulate Orofacial Neuromuscular Junction Regeneration via Myostatin
Background Orofacial and limb muscles differ in embryonic origin and regenerative capacity. Neuromuscular junction (NMJ) regeneration is critical for muscle restoration both histologically and functionally. The relative potential of orofacial and limb muscles to form postsynaptic apparatuses remains elusive.
review · 2026
Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025
Alongside the considerable advances and accomplishments in drug research and development, the breadth of anti-doping research topics has also continued to grow.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
review · 2026
Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders
Myostatin (Mstn), a well-characterized member of the transforming growth factor-β (TGF-β) superfamily, serves as a key negative regulator of skeletal muscle mass. Its overactivation is closely associated with the pathogenesis of various musculoskeletal and metabolic disorders.
Study · 2025
ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus)
ABSTRACT Aim Pharmacological blockade of ligands for the activin receptor type IIB (ActRIIB) e.g., myostatin and activin A is associated with improvements in murine skeletal muscle mass and function.